Despite the broad implication of multitargeting HDAC inhibitors in clinical practice (romidepsin, belinostat, panobinostat, and vorinostat) and trials (abexinostat, quisinostat, and resminostat), little is known about the relevance of individual HDACs as potential targets in leukemia and NB patients. This evidence concerns the gene HDAC9 and leukemia.